Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO)

References

• Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002;100(6):1997–2004.
   PubMed Web of Science ®Google Scholar
• Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104(2):579–85. doi: 10.1182/blood-2004-01-0338
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002;100(4):1201–7. doi: 10.1182/blood-2002-02-0527
   PubMed Web of Science ®Google Scholar
• Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004;104(6):1616–23. doi: 10.1182/blood-2003-12-4207
   PubMed Web of Science ®Google Scholar
• Kröger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A, et al. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia 2013;27(3):604–9. doi: 10.1038/leu.2012.210
   PubMed Web of Science ®Google Scholar
• Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998;92(6):1910–7.
   PubMed Web of Science ®Google Scholar
• Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007;110(4):1379–87. doi: 10.1182/blood-2007-02-076307
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008;112(3):895–902. doi: 10.1182/blood-2008-03-143735
   PubMed Web of Science ®Google Scholar
• Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009;15(1):30–8. doi: 10.1016/j.bbmt.2008.10.012
   PubMed Web of Science ®Google Scholar
• Busca A, Pecoraro C, Giaccone L, Bruno B, Allione B, Corsetti MT, et al. Allogeneic stem cell transplant for adults with myelodysplastic syndromes: relevance of pre-transplant disease status. Leuk Lymphoma 2014;55(4):863–9. doi: 10.3109/10428194.2013.816422
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079–88.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood 2012;120(12):2454–65. doi: 10.1182/blood-2012-03-420489
   PubMed Web of Science ®Google Scholar
• Armand P, Deeg HJ, Kim HT, Lee H, Armistead P, de Lima M, et al. Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant. 2010;45(5):877–85. doi: 10.1038/bmt.2009.253
   PubMed Web of Science ®Google Scholar
• Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012;120(4):905–13. doi: 10.1182/blood-2012-03-418202
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 2014;123(15):2333–42. doi: 10.1182/blood-2013-12-542720
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–33. doi: 10.1016/j.bbmt.2009.07.004
   PubMed Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statist Med. 1999;18(6):695–706. doi: 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi: 10.1080/01621459.1999.10474144
   Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8. doi: 10.1038/bmt.2012.244
   PubMed Web of Science ®Google Scholar
• Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008;26(4):577–84. doi: 10.1200/JCO.2007.11.1641
   PubMed Web of Science ®Google Scholar
• Hiramoto N, Kurosawa S, Tajima K, Okinaka K, Tada K, Kobayashi Y, et al. Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients. Eur J Haematol. 2014;92(2):137–46. doi: 10.1111/ejh.12214
   PubMed Web of Science ®Google Scholar
• Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015; http://doi.org/10.1038/leu.2015.37. [Epub ahead of print].
   Web of Science ®Google Scholar
• Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant. 2009;43(8):597–609. doi: 10.1038/bmt.2009.28
   PubMed Web of Science ®Google Scholar
• Luger SM, Ringdén O, Zhang MJ, Pérez WS, Bishop MR, Bornhauser M, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012;47(2):203–11. doi: 10.1038/bmt.2011.69
   PubMed Web of Science ®Google Scholar
• Oran B, Popat U, Andersson B, Champlin R. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2013;13(Suppl. 2):S282–8. doi: 10.1016/j.clml.2013.07.012
   PubMedGoogle Scholar
• Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002;99(6):1943–51. doi: 10.1182/blood.V99.6.1943
   PubMed Web of Science ®Google Scholar
• Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, et al. Reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008;14(2):246–55. doi: 10.1016/j.bbmt.2007.11.012
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, et al. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20(4):549–55. doi: 10.1016/j.bbmt.2014.01.009
   PubMed Web of Science ®Google Scholar
• Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor–mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002;99(12):4370–8. doi: 10.1182/blood.V99.12.4370
   PubMed Web of Science ®Google Scholar
• Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, et al. Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant. 2015;21(1):55–9. doi: 10.1016/j.bbmt.2014.09.006
   PubMed Web of Science ®Google Scholar
• Shimoni A, Shem-Tov N, Volchek Y, Danylesko I, Yerushalmi R, Nagler A. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Bone Marrow Transplant. 2012;47(10):1274–82. doi: 10.1038/bmt.2012.4
   PubMed Web of Science ®Google Scholar
• Servais S, Porcher R, Xhaard A, Robin M, Masson E, Larghero J, et al. Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors. Haematologica 2014;99(3):519–26. doi: 10.3324/haematol.2013.089979
   PubMed Web of Science ®Google Scholar
• Basquiera AL, Pizzi S, Correas AG, Longo PG, Goldman WC, Prates MV, et al. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina. Pediatr Blood Cancer 2015;62(1):153–7. doi: 10.1002/pbc.25238
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 2013;122(19):3359–64. doi: 10.1182/blood-2013-05-499830
   PubMed Web of Science ®Google Scholar